Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation

Summary

This is a single-center, parallel-group, randomized, open-label trial evaluating the effect of 3-month treatment with dapagliflozin 10mg once daily on the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation in patients without diabetes, heart failure, or chronic kidney disease.

Timeline

Start

2024-07-15

Primary completion

2025-07-01

Completion

2025-07-01

Outcome

Missed primary endpoint

paper the difference in AF burden was insignificant between the dapagliflozin group and the control group (7.5±23.6% versus 8.1±25.5%; P=0.48). PMID 41206792 ↗

Publications

• Jiang C, Zhao Z, Yang Z, Wang Y, Xu Y, Xu H, Guo H, Wang C, He L, Xia S, Kong X, Dai W, Zhang J, Zuo S, Liu X, Guo X, Liu N, Li S, Zhou N, Jiang C, Tang R, Sang C, Zei PC, Long D, Du X, Dong J, Macle L, Ma C. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Circulation. 2026 Feb 3;153(5):297-306. doi: 10.1161/CIRCULATIONAHA.125.077447. Epub 2025 Nov 9.

Drugs

Indications